Stage IV Colorectal Cancer Patients with High Risk Mutation Profiles Survived 16 Months Longer with Individualized Therapies
Personalized treatment vs. standard of care is much debated, especially in clinical practice. Here we investigated whether overall survival differences in metastatic colorectal cancer patients are explained by tumor mutation profiles or by treatment differences in real clinical practice. Our retrosp...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-02-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/2/393 |
id |
doaj-c6f980508f8e4564be42eef7097f4819 |
---|---|
record_format |
Article |
spelling |
doaj-c6f980508f8e4564be42eef7097f48192020-11-25T02:03:34ZengMDPI AGCancers2072-66942020-02-0112239310.3390/cancers12020393cancers12020393Stage IV Colorectal Cancer Patients with High Risk Mutation Profiles Survived 16 Months Longer with Individualized TherapiesAlexander Hendricks0Anu Amallraja1Tobias Meißner2Peter Forster3Philip Rosenstiel4Greta Burmeister5Clemens Schafmayer6Andre Franke7Sebastian Hinz8Michael Forster9Casey B. Williams10Department of General and Thoracic Surgery, University Hospital Schleswig-Holstein Campus Kiel, 24105 Kiel, GermanyDepartment of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, SD 57105, USADepartment of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, SD 57105, USAMcDonald Institute for Archaeological Research, University of Cambridge, Cambridge CB2 1TN, UKInstitute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, 24105 Kiel, GermanyDepartment of General and Thoracic Surgery, University Hospital Schleswig-Holstein Campus Kiel, 24105 Kiel, GermanyDepartment of General and Thoracic Surgery, University Hospital Schleswig-Holstein Campus Kiel, 24105 Kiel, GermanyInstitute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, 24105 Kiel, GermanyDepartment of General and Thoracic Surgery, University Hospital Schleswig-Holstein Campus Kiel, 24105 Kiel, GermanyInstitute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, 24105 Kiel, GermanyDepartment of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, SD 57105, USAPersonalized treatment vs. standard of care is much debated, especially in clinical practice. Here we investigated whether overall survival differences in metastatic colorectal cancer patients are explained by tumor mutation profiles or by treatment differences in real clinical practice. Our retrospective study of metastatic colorectal cancer patients of confirmed European ancestry comprised 54 Americans and 54 gender-matched Germans. The Americans received standard of care, and on treatment failure, 35 patients received individualized treatments. The German patients received standard of care only. Tumor mutations, tumor mutation burden and microsatellite status were identified by using the FoundationOne assay or the IDT Pan-Cancer assay. High-risk patients were identified according to the mutational classification by Schell and colleagues. <i>Results</i>: Kaplan−Meier estimates show the high-risk patients to survive 16 months longer under individualized treatments than those under only standard of care, in the median (<i>p</i> < 0.001). Tumor mutation profiles stratify patients by risk groups but not by country. <i>Conclusions</i>: High-risk patients appear to survive significantly longer (<i>p</i> < 0.001) if they receive individualized treatments after the exhaustion of standard of care treatments. Secondly, the tumor mutation landscape in Americans and Germans is congruent and thus warrants the transatlantic exchange of successful treatment protocols and the harmonization of guidelines.https://www.mdpi.com/2072-6694/12/2/393metastatic colorectal cancermutational landscapetreatmentoverall survival |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Alexander Hendricks Anu Amallraja Tobias Meißner Peter Forster Philip Rosenstiel Greta Burmeister Clemens Schafmayer Andre Franke Sebastian Hinz Michael Forster Casey B. Williams |
spellingShingle |
Alexander Hendricks Anu Amallraja Tobias Meißner Peter Forster Philip Rosenstiel Greta Burmeister Clemens Schafmayer Andre Franke Sebastian Hinz Michael Forster Casey B. Williams Stage IV Colorectal Cancer Patients with High Risk Mutation Profiles Survived 16 Months Longer with Individualized Therapies Cancers metastatic colorectal cancer mutational landscape treatment overall survival |
author_facet |
Alexander Hendricks Anu Amallraja Tobias Meißner Peter Forster Philip Rosenstiel Greta Burmeister Clemens Schafmayer Andre Franke Sebastian Hinz Michael Forster Casey B. Williams |
author_sort |
Alexander Hendricks |
title |
Stage IV Colorectal Cancer Patients with High Risk Mutation Profiles Survived 16 Months Longer with Individualized Therapies |
title_short |
Stage IV Colorectal Cancer Patients with High Risk Mutation Profiles Survived 16 Months Longer with Individualized Therapies |
title_full |
Stage IV Colorectal Cancer Patients with High Risk Mutation Profiles Survived 16 Months Longer with Individualized Therapies |
title_fullStr |
Stage IV Colorectal Cancer Patients with High Risk Mutation Profiles Survived 16 Months Longer with Individualized Therapies |
title_full_unstemmed |
Stage IV Colorectal Cancer Patients with High Risk Mutation Profiles Survived 16 Months Longer with Individualized Therapies |
title_sort |
stage iv colorectal cancer patients with high risk mutation profiles survived 16 months longer with individualized therapies |
publisher |
MDPI AG |
series |
Cancers |
issn |
2072-6694 |
publishDate |
2020-02-01 |
description |
Personalized treatment vs. standard of care is much debated, especially in clinical practice. Here we investigated whether overall survival differences in metastatic colorectal cancer patients are explained by tumor mutation profiles or by treatment differences in real clinical practice. Our retrospective study of metastatic colorectal cancer patients of confirmed European ancestry comprised 54 Americans and 54 gender-matched Germans. The Americans received standard of care, and on treatment failure, 35 patients received individualized treatments. The German patients received standard of care only. Tumor mutations, tumor mutation burden and microsatellite status were identified by using the FoundationOne assay or the IDT Pan-Cancer assay. High-risk patients were identified according to the mutational classification by Schell and colleagues. <i>Results</i>: Kaplan−Meier estimates show the high-risk patients to survive 16 months longer under individualized treatments than those under only standard of care, in the median (<i>p</i> < 0.001). Tumor mutation profiles stratify patients by risk groups but not by country. <i>Conclusions</i>: High-risk patients appear to survive significantly longer (<i>p</i> < 0.001) if they receive individualized treatments after the exhaustion of standard of care treatments. Secondly, the tumor mutation landscape in Americans and Germans is congruent and thus warrants the transatlantic exchange of successful treatment protocols and the harmonization of guidelines. |
topic |
metastatic colorectal cancer mutational landscape treatment overall survival |
url |
https://www.mdpi.com/2072-6694/12/2/393 |
work_keys_str_mv |
AT alexanderhendricks stageivcolorectalcancerpatientswithhighriskmutationprofilessurvived16monthslongerwithindividualizedtherapies AT anuamallraja stageivcolorectalcancerpatientswithhighriskmutationprofilessurvived16monthslongerwithindividualizedtherapies AT tobiasmeißner stageivcolorectalcancerpatientswithhighriskmutationprofilessurvived16monthslongerwithindividualizedtherapies AT peterforster stageivcolorectalcancerpatientswithhighriskmutationprofilessurvived16monthslongerwithindividualizedtherapies AT philiprosenstiel stageivcolorectalcancerpatientswithhighriskmutationprofilessurvived16monthslongerwithindividualizedtherapies AT gretaburmeister stageivcolorectalcancerpatientswithhighriskmutationprofilessurvived16monthslongerwithindividualizedtherapies AT clemensschafmayer stageivcolorectalcancerpatientswithhighriskmutationprofilessurvived16monthslongerwithindividualizedtherapies AT andrefranke stageivcolorectalcancerpatientswithhighriskmutationprofilessurvived16monthslongerwithindividualizedtherapies AT sebastianhinz stageivcolorectalcancerpatientswithhighriskmutationprofilessurvived16monthslongerwithindividualizedtherapies AT michaelforster stageivcolorectalcancerpatientswithhighriskmutationprofilessurvived16monthslongerwithindividualizedtherapies AT caseybwilliams stageivcolorectalcancerpatientswithhighriskmutationprofilessurvived16monthslongerwithindividualizedtherapies |
_version_ |
1724947347832569856 |